Innovative Bioanalysis Lab

CLIA Laboratory Citation Details

1
Total Citation
7
Total Deficiencyies
7
Unique D-Tags
CMS Certification Number 05D0955926
Address 3188 Airway Ave Suite D, Costa Mesa, CA, 92626
City Costa Mesa
State CA
Zip Code92626
Phone(949) 674-5938

Citation History (1 survey)

Survey - May 1, 2019

Survey Type: Standard

Survey Event ID: CIOX11

Deficiency Tags: D2075 D2121 D5217 D2020 D2087 D5215 D6019

Summary:

Summary Statement of Deficiencies D2020 BACTERIOLOGY CFR(s): 493.823(a) Failure to attain an overall testing event score of at least 80 percent is unsatisfactory performance. This STANDARD is not met as evidenced by: Based on review of the third quarter (Q3-2017) of the American Association of Bioanalyts (AAB) proficiency testing records, random patient sampling test results, and interview with the technical consultant, it was determined that the laboratory failed to attain a score of at least 80 percent of acceptable responses for Culture ID. The findings included: a. Q3-2017, AAB reported 66.7% for Culture ID. b. For eight (8) out of eight (8) random patient sampling test results reviewed covering period from 9/28/2017 to 11/6/2017, the laboratory analyzed and reported Culture ID, during the time the laboratory received an unsatisfactory proficiency testing score. c. The technical consultant confirmed (5/1/2019, 1300), that the laboratory received the above unsatisfactory proficiency test score. D2075 GENERAL IMMUNOLOGY CFR(s): 493.837(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on review of the first quarter (Q1-2017) of the American Association of Bioanalyts (AAB) proficiency testing records, random patient sampling test results, and interview with the technical consultant, it was determined that the laboratory failed to attain a score of at least 80 percent of acceptable responses for Rheumatoid Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- Factor (RF). The findings included: a. Q1-2017, AAB reported 60% for RF analyte. b. For three (3) out of five (5) random patient sampling test results reviewed covering period from 2/14/2017 to 3/22/2017, the laboratory analyzed and reported RF analyte during the time the laboratory received an unsatisfactory proficiency testing score. c. The technical consultant confirmed (5/1/2019, 1300), that the laboratory received the above unsatisfactory proficiency test score. D2087 ROUTINE CHEMISTRY CFR(s): 493.841(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on review of the first quarter (Q1-2019) of the American Association of Bioanalyts (AAB) proficiency testing records, random patient sampling test results, and interview with the technical supervisor, it was determined that the laboratory failed to attain a score of at least 80 percent of acceptable responses for Creatinine Kinase (CK), and Cholesterol, Total analytes. The findings included: a. Q1-2019, AAB reported the following unsatisfactory testing score Analyte: Score: Event/Year: CK 0% Q1-2018 Chol, Total 60% Q1-2019 b. For eight (8) out of eight (8) random patient test results reviewed covering period from 1/8/2019 to 3/22/2019, the laboratory analyzed and reported CK, and Chol, Total tests during the approximate time the laboratory failed the proficiency testing. c. The technical consultant confirmed (5/1/2019, 1300) that the laboratory received the above unsatisfactory proficiency testing score for CK, and Cholesterol, Total analytes. D2121 HEMATOLOGY CFR(s): 493.851(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on review of the second quarter (Q2-2018) of the American Association of Bioanalyts (AAB) proficiency testing records, random patient sampling test results, and interview with the technical supervisor, it was determined that the laboratory failed to attain a score of at least 80 percent of acceptable responses for White Blood Cell (WBC) count. The findings included: a. Q2-2018, AAB reported the following unsatisfactory testing scores. Analyte: Score: Event/Year: WBC PMN 0% Q2-2018 WBC Lymph 0% Q2-2018 WBC Mono 50% Q2-2018 b. For three (3) out of three (3) random patient sampling test results reviewed covering period from 6/15/2018 to 6/27 /2018 the laboratory analyzed and reported Complete Blood Count (CBC) with WBC differentials that cannot be assured. c. The technical supervisor confirmed (5/1/2019, 1300), that the laboratory received the above unsatisfactory proficiency test score. D5215 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(b)(2) The laboratory must verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance -- 2 of 4 -- (that is, when the proficiency testing program does not obtain the agreement required for scoring as specified in subpart I of this part, or the laboratory receives a zero score for nonparticipation, or late return or results). This STANDARD is not met as evidenced by: Based on review of the first quarter (Q1-2018) American Association of Bioanalysts (AAB) proficiency testing records and interview with the technical consultant, it was determined that the laboratory failed to verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance. The findings included: a. Q1-2018, AAB proficiency testing, the laboratory received an artificial 100% score for High Density Lipoprotein (HDL, Cholesterol) analyte. Spec.: Reported Grading Mean: Value: Range: 1# 56 24-45 34.8 2 # 148 75-139 107.1 3# 75 33-61 46.6 4# 29 12-23 17.6 5# 15 7-12 9.3 Q2-2018 Spec.: Reported Grading Mean: Value: Range: 1# 3 12-22 16.9 2 # 10 30-57 43.5 3# 49 71-132 71 4# 1 6-12 8.9 5# 7 23-43 33.4 Note: True score for HDL, Cholesterol should have been 0% for Q1-2018, and Q2-2018. b. For eight (8) out of eight (8) random patient test results reviewed covering period from 1/8/2019 to 3/22/2019, the laboratory analyzed and reported HDL, Chol tests that results cannot be assured. c. The technical consultant confirmed (5/1/2019, 1300) that the laboratory received the above artificial 100% score for HDL, Chol and that the laboratory did not have a

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access